Compare CVS Health Corp (CVS) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Koninklijke Philips NV — how do they compare? CVS Health Corp trades at $95.29 (market cap $119.58B), while Koninklijke Philips NV trades at $26.84 (market cap $26.58B). The key difference: CVS Health Corp is far larger — about 4.5× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| CVS | PHG | |
|---|---|---|
Market Cap | $119.58B | $26.58B |
Sector | Health | Health |
52-Week High | $110.60 | $32.91 |
52-Week Low | $65.90 | $25.02 |
Enterprise Value | $181.93B | $33.13B |
Dividend Yield | 2.84% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $94.70, down 1.01% with strong technical support at $93-$91 levels. The company reported robust Q2 2026 earnings of $2.58 per share, beating estimates by 38%, while raising full-year guidance. Revenue growth accelerated to 7.3% year-over-year, driven by Aetna's recovery and retail strength. Analyst consensus remains overwhelmingly bullish with 84% buy ratings and a $115.90 price target representing 22% upside potential.
CVS presents compelling value with a 0.29 P/S ratio and positive earnings momentum, though net margins remain thin at 1.18%. Key risks include 2027 PBM pressure and healthcare regulatory changes. The stock's current technical weakness near support levels offers potential entry point for long-term investors seeking exposure to integrated healthcare services.
PHG trades at $26.86, down 0.3% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after previous losses. Recent news highlights Exor's potential stake increase to 22% and FDA clearances for new medical devices, while analyst sentiment remains mixed with 41% buy ratings.
The outlook appears cautiously optimistic with solid earnings momentum and institutional accumulation, though risks include order intake volatility and competitive pressures. The stock offers value characteristics with reasonable P/E of 20.5 and strong cash flow generation, but investors should monitor execution on growth initiatives and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
